AARTI DRUGS LTD. - 524348 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Please find attached herewith press release on Financial Results for the quarter and Year ended March 31, 202209-05-2022
09-05-2022
AARTI DRUGS LTD. - 524348 - Announcement under Regulation 30 (LODR)-Investor Presentation
Please find attached herewith Q4FY22 Results presentation of the Company for your records.09-05-2022
AARTI DRUGS LTD. - 524348 - Announcement under Regulation 30 (LODR)-Change in Directorate
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that, based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors at its meeting held today appointed Prof. Bhaskar Narayan Thorat (DIN: 01293824) and CA Neha Rajen Gada (DIN: 01642373) as an Additional Directors in the category of an Independent Director of the Company with effect from May 9, 2022 for the period of three years subject to approval of the Shareholders of the Company.09-05-2022
AARTI DRUGS LTD. - 524348 - Audited Financial Results Of The Company (Standalone And Consolidated) For The Quarter And Year Ended March 31, 2022
We wish to inform you that Board of Directors at its Meeting held on Monday, May 9, 2022, approved the Audited Financial Results of the Company (Standalone and Consolidated) for the Quarter and Year ended March 31, 2022. In this regards we enclose; i. Statement showing the Financial Results (Standalone and Consolidated), ii. Statement of Assets and Liabilities (Standalone and Consolidated), iii. Cash Flow Statement (Standalone and Consolidated) iv. Auditor's Report on the Financial Results (Standalone and Consolidated), v. Declaration in respect of Audit reports with unmodified opinion for the Financial Year ended March 31, 202209-05-2022
AARTI DRUGS LTD. - 524348 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
This is to inform you that Quarterly Conference Call for the Investors and Analysts has been scheduled on Tuesday, May 10, 2022 at 4:00 PM IST to discuss the Company's financial performance for the Quarter and year ended March 31, 2022. Please find attached herewith invitation for the same.05-05-2022
AARTI DRUGS LTD. - 524348 - Board Meeting Intimation for Audited Financial Results
AARTI DRUGS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/05/2022 ,inter alia, to consider and approve and take on record Audited Financial Results for the Quarter and year ended March 31, 2022.02-05-2022
AARTI DRUGS LTD. - 524348 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayAARTI DRUGS LTD. 2CINL37060MH1984PLC055433 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 118.33 4Highest Credit Rating during the previous FY AA- 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)CRISIL LTD. 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkNSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Rushikesh Deole Designation: Company Secretary EmailId: [email protected] Name of the Chief Financial Officer: Adhish P Patil Designation: Chief Financial Officer EmailId: [email protected] Date: 30/04/2022 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.30-04-2022
AARTI DRUGS LTD. - 524348 - Compliance Of Regulation 40(10) Of SEBI (LODR) Regulations, 2015 For The Half Year Ended March 31, 2022
We are forwarding herewith Certificate under Regulation 40(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 received from Jagdish Patel & Co., Practicing Company Secretary, for the half year ended March 31, 2022 for your perusal and record.16-04-2022
AARTI DRUGS LTD. - 524348 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Please find enclose herewith a Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2022 received from Link Intime India Private Limited, Registrar and Share Transfer Agent of our Company.08-04-2022